Clinigen Group (OTCMKTS:CLIGF) Upgraded to “Hold” by Zacks Investment Research

Zacks Investment Research upgraded shares of Clinigen Group (OTCMKTS:CLIGF) from a strong sell rating to a hold rating in a research note released on Tuesday, reports.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

CLIGF has been the topic of several other research reports. Royal Bank of Canada restated an outperform rating on shares of Clinigen Group in a report on Wednesday, July 7th. Stifel Nicolaus lowered Clinigen Group from a buy rating to a hold rating in a report on Thursday, June 10th.

OTCMKTS:CLIGF opened at $8.65 on Tuesday. The stock’s fifty day moving average is $8.43 and its 200 day moving average is $8.85. Clinigen Group has a fifty-two week low of $8.24 and a fifty-two week high of $11.56. The firm has a market capitalization of $1.06 billion, a PE ratio of 10.68 and a beta of 0.72. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.33 and a current ratio of 1.73.

Clinigen Group Company Profile

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines.

Recommended Story: How do buyers and sellers choose a strike price?

Get a free copy of the Zacks research report on Clinigen Group (CLIGF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with's FREE daily email newsletter.